BNTX Relative Valuation
BNTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BNTX is overvalued; if below, it's undervalued.
Historical Valuation
Biontech SE (BNTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.29 is considered Undervalued compared with the five-year average of 5.70. The fair price of Biontech SE (BNTX) is between 632.14 to 685.09 according to relative valuation methord. Compared to the current price of 98.68 USD , Biontech SE is Undervalued By 84.39%.
Relative Value
Fair Zone
632.14-685.09
Current Price：98.68
84.39%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.05
P/B
Median3y
1.39
Median5y
6.25
-2.68
FCF Yield
Median3y
23.17
Median5y
14.17
Competitors Valuation Multiple
The average P/S ratio for BNTX's competitors is 220.66, providing a benchmark for relative valuation. Biontech SE Corp (BNTX) exhibits a P/S ratio of 8.29, which is -96.24% above the industry average. Given its robust revenue growth of -2.56%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Biontech SE (BNTX) currently overvalued or undervalued?
What is Biontech SE (BNTX) fair value?
How does BNTX's valuation metrics compare to the industry average?
What is the current P/B ratio for Biontech SE (BNTX) as of May 24 2025?
What is the current FCF Yield for Biontech SE (BNTX) as of May 24 2025?
What is the current Forward P/E ratio for Biontech SE (BNTX) as of May 24 2025?